UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 15, 2003
Targeted Genetics Corporation
(Exact name of registrant as specified in charter)
| Washington | 0-23930 | 91-1549568 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 1100 Olive Way, Suite 100, Seattle, Washington | 98101 | |
| (Address of principal executive offices) | (Zip Code) |
(206) 623-7612
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
| Item 5. | Other Events. |
On July 15, 2003, Targeted Genetics Corporation announced the initiation of a Phase IIb clinical trial of tgAAVCF in patients with cystic fibrosis. The text of the press release is set forth in Exhibit 99.1 attached to this release and incorporated herein by this reference.
| Item 7. | Exhibits. |
| (a) | Financial statements of business acquired. |
Not applicable.
| (b) | Pro forma financial information. |
Not applicable.
| (c) | Exhibits. |
| Exhibit No. |
Description | |
| 99.1 |
Press Release dated July 15, 2003 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TARGETED GENETICS CORPORATION
| ||||||||
| Date: July 16, 2003 | By: | /s/ TODD E. SIMPSON | ||||||
| Todd E. Simpson Vice President, Finance and Administration and Chief Financial Officer, Secretary and Treasurer (Principal Financial and Accounting Officer) | ||||||||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 |
Press Release dated July 15, 2003 |